Trexquant Investment LP Has $14.15 Million Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)

Trexquant Investment LP raised its position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 43.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 313,417 shares of the biopharmaceutical company's stock after buying an additional 95,418 shares during the period. Trexquant Investment LP owned about 0.41% of PTC Therapeutics worth $14,148,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Smartleaf Asset Management LLC boosted its holdings in PTC Therapeutics by 78.7% in the fourth quarter. Smartleaf Asset Management LLC now owns 613 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 270 shares during the last quarter. Venturi Wealth Management LLC acquired a new position in PTC Therapeutics during the 4th quarter valued at about $68,000. R Squared Ltd bought a new position in shares of PTC Therapeutics in the 4th quarter valued at about $79,000. KBC Group NV grew its position in shares of PTC Therapeutics by 36.4% during the 4th quarter. KBC Group NV now owns 3,045 shares of the biopharmaceutical company's stock worth $137,000 after buying an additional 813 shares during the period. Finally, Savant Capital LLC bought a new stake in shares of PTC Therapeutics during the fourth quarter worth approximately $210,000.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Citigroup lifted their target price on shares of PTC Therapeutics from $32.00 to $45.00 and gave the stock a "sell" rating in a report on Wednesday, February 12th. Royal Bank of Canada lifted their price objective on PTC Therapeutics from $60.00 to $63.00 and gave the stock an "outperform" rating in a research note on Tuesday, February 18th. Cantor Fitzgerald increased their target price on PTC Therapeutics from $76.00 to $113.00 and gave the company an "overweight" rating in a research note on Monday, February 3rd. Morgan Stanley restated an "overweight" rating and set a $70.00 target price (up previously from $67.00) on shares of PTC Therapeutics in a report on Friday, March 7th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of PTC Therapeutics from $78.00 to $75.00 and set an "overweight" rating on the stock in a research note on Monday, March 31st. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $63.77.

Remove Ads

Insider Transactions at PTC Therapeutics

In related news, VP Mark Elliott Boulding sold 1,543 shares of the business's stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $45.34, for a total transaction of $69,959.62. Following the transaction, the vice president now directly owns 108,846 shares of the company's stock, valued at approximately $4,935,077.64. The trade was a 1.40 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Lee Scott Golden sold 795 shares of the stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $50.10, for a total transaction of $39,829.50. Following the completion of the transaction, the executive vice president now directly owns 77,856 shares in the company, valued at $3,900,585.60. The trade was a 1.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 36,009 shares of company stock worth $1,841,161 in the last ninety days. Insiders own 5.50% of the company's stock.

PTC Therapeutics Price Performance

PTCT stock traded down $3.49 during midday trading on Friday, hitting $43.24. The company's stock had a trading volume of 1,309,479 shares, compared to its average volume of 799,625. The company's fifty day moving average price is $51.22 and its 200 day moving average price is $45.63. PTC Therapeutics, Inc. has a twelve month low of $24.00 and a twelve month high of $58.38. The stock has a market capitalization of $3.41 billion, a P/E ratio of -7.28 and a beta of 0.58.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.